Maysiglu

Sitagliptin, the active ingredient in Maysiglu, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control when used with diet and exercise.

GNH USA supplies Maysiglu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maysiglu, a DPP-4 inhibitor, is indicated for managing type 2 diabetes mellitus and related glycaemic control pathways.

- Type 2 diabetes mellitus: improves blood glucose levels when combined with diet and exercise. - Inadequate control on metformin alone: provides additional glucose‑lowering effect. - Combination therapy with other oral antidiabetics: enhances overall glycaemic management.

Maysiglu may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasopharyngitis: mild upper respiratory symptoms. - Headache: transient cranial discomfort. - Nausea: occasional stomach upset. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia. - Hepatic injury: elevated liver enzymes. - Bullous pemphigoid: blistering skin disorder.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal function: assess and adjust dosing in impaired patients. - Pancreatitis history: monitor for abdominal pain and elevated enzymes. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Elderly patients: use caution due to potential comorbidities. - Hepatic impairment: evaluate liver function before use. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Sitagliptin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise plasma levels. - Insulin secretagogues combined with high‑dose sulfonylureas: risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure and renal function. - Diuretics: watch for electrolyte disturbances. - Warfarin: check INR more frequently due to potential bleeding risk.